摘要
目的探讨孟鲁司特钠联合布地奈德福莫特罗治疗哮喘-慢阻肺重叠综合征(ACOS)患者的临床效果。方法选取2019年2月至2022年2月我院收治的60例ACOS患者,随机分为两组各30例。参照组采用布地奈德福莫特罗治疗,试验组采用孟鲁司特钠联合布地奈德福莫特罗治疗。比较两组的治疗效果、肺功能及不良反应。结果试验组的治疗总有效率为93.33%,高于参照组的70.00%(P<0.05)。治疗后,两组的FEV_(1)、FVC及FEV_(1)/FVC均较治疗前升高,且试验组的上述指标水平均高于参照组(P<0.05)。两组治疗期间的不良反应总发生率比较,差异无统计学意义(6.67%vs.10.00%,P>0.05)。结论孟鲁司特钠联合布地奈德福莫特罗治疗ACOS可显著提升临床疗效,改善患者肺功能,且安全性较高。
Objective To explore the clinical effect of montelukast sodium combined with budesonide formoterol in the treatment of patients with asthma-chronic obstructive pulmonary overlap syndrome(ACOS).Methods Sixty patients with ACOS admitted to our hospital from February 2019 to February 2022 were selected and randomly divided into two groups,with 30 cases in each group.The reference group was treated with budesonide formoterol,and the experimental group was treated with montelukast sodium combined with budesonide formoterol.The therapeutic effect,lung function and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the experimental group was 93.33%,higher than 70.00%in the reference group(P<0.05).After treatment,FEV_(1),FVC and FEV_(1)/FVC in the two groups were higher than those before treatment,and the above indicators in the experimental group were higher than those in the reference group(P<0.05).No significant difference was found in the total incidence of adverse reactions during treatment between the two groups(6.67%vs.10.00%,P>0.05).Conclusions Montelukast sodium combined with budesonide formoterol in the treatment of ACOS can significantly improve the clinical efficacy,improve the lung function of patients,and has higher safety.
作者
张娟娟
马超楠
马威
ZHANG Juanjuan;MA Chaonan;MA Wei(Department of Respiratory and Critical Care Medicine,Huaihe Hospital of He'nan University,Kaifeng 475000,China)
出处
《临床医学工程》
2023年第8期1099-1100,共2页
Clinical Medicine & Engineering
关键词
孟鲁司特钠
布地奈德福莫特罗
哮喘-慢阻肺重叠综合征
临床疗效
Montelukast sodium
Formoterol budesonide
Asthma-chronic obstructive pulmonary overlap syndrome
Clinical efficacy
